Phospho-HSPB1 (Ser82) Antibody

Shipped with Ice Packs
In Stock

Product Specs

Form
Supplied at 1.0 mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship the products within 1-3 business days after receiving your order. Delivery time may vary depending on the purchasing method or location. Please consult your local distributors for specific delivery times.
Synonyms
Heat shock 27kDa protein antibody; 28 kDa heat shock protein antibody; CMT2F antibody; DKFZp586P1322 antibody; epididymis secretory protein Li 102 antibody; Estrogen regulated 24 kDa protein antibody; Estrogen-regulated 24 kDa protein antibody; Heat shock 25kDa protein 1 antibody; Heat shock 27 kDa protein antibody; Heat shock 27kD protein 1 antibody; Heat shock 27kDa protein 1 antibody; Heat shock 28kDa protein 1 antibody; Heat Shock Protein 27 antibody; Heat shock protein beta 1 antibody; Heat shock protein beta-1 antibody; heat shock protein family B (small) member 1 antibody; HEL-S-102 antibody; HMN2B antibody; HS.76067 antibody; Hsp 25 antibody; HSP 27 antibody; Hsp 28 antibody; Hsp B1 antibody; Hsp25 antibody; HSP27 antibody; Hsp28 antibody; HspB1 antibody; HSPB1_HUMAN antibody; SRP27 antibody; Stress responsive protein 27 antibody; Stress-responsive protein 27 antibody
Target Names
Uniprot No.

Target Background

Function
Phospho-HSPB1 (Ser82) Antibody targets the small heat shock protein HSPB1, which functions as a molecular chaperone. This protein likely maintains denatured proteins in a state that is competent for folding. It plays a role in stress resistance and actin organization. Through its molecular chaperone activity, it may regulate numerous biological processes, including the phosphorylation and axonal transport of neurofilament proteins.
Gene References Into Functions
  1. Data suggest that both the small heat shock protein HspB1/Hsp27 and the constitutive chaperone Hsc70/HspA8 interact with tau to prevent tau-fibril/amyloid formation. HspB1 delays tau-fibril formation by weakly interacting with early species in the aggregation process. (HspB1 = heat shock protein family B small member 1; Hsc70 = heat shock protein family A Hsp70) PMID: 29298892
  2. HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. PMID: 29650953
  3. Results show that HSP27 expression is significantly increased in metastatic prostate cancer and represents a strong marker predicting survival, along with ALDH6A1 and prohibitin. PMID: 30396985
  4. High HSP27 expression is associated with breast cancer. PMID: 30106436
  5. Our data suggest that overexpression of peroxiredoxin-2, annexin A2, and heat shock protein beta-1 was correlated with tumor invasion, metastasis, and poor prognosis, and therefore, these proteins may serve as potential diagnostic and therapeutic biomarkers. PMID: 29332450
  6. ETAS down-regulated HSP27 and pHSP27 (serine 78) in KLM1-R cells, but, HSP70 and GRP78 levels were not altered. This study suggests the potential therapeutic benefit of ETAS in enhancing anticancer effects by its combination with gemcitabine for patients with pancreatic cancer PMID: 29936456
  7. Silencing of HSP27 increases curcumin resistance by reducing apoptosis and reactive oxidative stress production in colon cancer. PMID: 30056019
  8. The expression of type I and III collagen in the TGF-beta1induced transition of A549 cells to myofibroblasts was significantly downregulated by transfection of A549 cells with HSP27 plasmid Dinterfering sequence and optimal ratio of Lipofectamine(R) 2000 and HSP27 plasmid. PMID: 29568951
  9. It was suggested that the HSP27 expression in EUS-FNA samples was useful for predicting GEM sensitivity. PMID: 29695571
  10. High hsp27 expression is associated with leukemia. PMID: 29328466
  11. p-Hsp27 is a novel biomarker of glioma and might have important clinical value for further classification of patients with wild-type IDH1 and normal ATRX expression and for evaluating prognosis. PMID: 29550762
  12. Dimer-monomer equilibrium of human HSP27 is influenced by the in-cell macromolecular crowding environment and is controlled by fatty acids and heat. PMID: 29635040
  13. HSP27 expression promotes vascular smooth muscle cell viability, suppresses cell apoptosis, and confers protection against oxidative stress in Thoracic aortic dissection. PMID: 29209372
  14. Hsp27 and P38MAPK could be used as prognostic factors in Esophageal squamous cell carcinoma. PMID: 29099815
  15. Addition of apatorsen to chemotherapy does not improve outcomes in unselected patients with metastatic pancreatic cancer in the first-line setting, although a trend toward prolonged PFS and OS in patients with high baseline serum Hsp27 suggests this therapy may warrant further evaluation in this subgroup PMID: 28935773
  16. High HSP27 expression is associated with non-small cell lung cancer metastasis. PMID: 28656293
  17. Knockdown of HSP27 blocked TGF-beta-induced cisplatin resistance. PMID: 28848138
  18. The expression of HSP27 was approximately 2-fold higher in apical periodontitis. Next, an increased expression of HSP27 was detected in epithelial cells PMID: 28673495
  19. Findings indicate the heat-shock protein 27 (Hsp27) pathway as a therapeutic target for the management of conditions featuring dysregulated interleukin 1 beta (IL-1beta) production. PMID: 27976724
  20. Increased protein level of HSP27 through SUMO2/3-mediated SUMOylation plays crucial roles in the progression of primary hepatocellular carcinoma. PMID: 28665748
  21. When the correlations of the markers with the response to neoadjuvant chemotherapy were examined, only high pre-chemotherapy levels of cytoplasmic HSPB1/p correlated with a poor clinical and pathological response to neoadjuvant cisplatin chemotherapy (p = 0.056) suggesting that this marker could be useful opening its study in a larger number of cases. PMID: 28608263
  22. Exposure to cetuximab and various concentration of AG490, an inhibitor of JAK2, STAT3 and HSP27 protein levels, except in the KRAS G12V mutant line, SW620...cetuximab may promote SN38 sensitivity via suppression of HSP27, through blocking the JAK/STAT signaling pathway, and shows synergistic effects when combined with SN38 in wild-type RAS CRC cells. PMID: 28656305
  23. we concluded that HSP27-silenced placenta-derived multipotent cells differentiated into neurons possessing the characteristics of functional glutamatergic neurons. PMID: 27444754
  24. Data show that Hsp27increases degradation rate of ubiquitinated MST1 and therefore interrupts the Hippo pathway kinase cascade. Consequently YAP and TAZ are less phosphorylated, free to translocate into the nucleus promoting a malignant phenotype. These findings underscore the central importance of Hsp27 in regulating multiple signaling pathways that promote tumor aggressiveness. PMID: 27555231
  25. upregulation of Hsp27 is a common phenomenon shared between pregnancies in patients with preterm prelabor rupture of membranes and spontaneous preterm labor with intact membranes PMID: 28497897
  26. HSP27 is an independent predictor of prognosis in chronic HF PMID: 28844461
  27. Hsp27 may up-regulate the expression of ABCA1 and promotes cholesterol efflux through activation of the PI3K/PKCzeta/Sp1 signal pathway in THP-1 macrophage-derived foam cells PMID: 28610841
  28. This study reports solution-state nuclear magnetic resonance spectroscopy investigations of the conformation and dynamics of the disordered and flexible C-terminal region of human HSP27. These data indicate a potential role for cis-trans proline isomerization in regulating the oligomerization. PMID: 28547731
  29. Overexpression of both HSPB5 and Hsp27 significantly reduced the intracellular aggregation of alpha-synuclein. PMID: 28337642
  30. HspB1 structural organization displays dynamic and complex rearrangements in response to changes in the cellular environment or when the cell physiology is modified. [review] PMID: 28144778
  31. Glutathione-S-transferase - HspB1 fusion protein prevents more aggregation of malate dehydrogenase compared to glutathione-S-transferase -HspB5 fusion protein and wild type HspB1. PMID: 28130664
  32. The data suggest that oncogene-addicted cells require the small heat-shock protein of 27 kDa (HSP27) for survival and that HSP27 might interfere with the effectiveness of targeted agents. PMID: 28182330
  33. Data indocate six cytostatic drugs which inhibit heat shock 27 kDa protein (HSP27) and tackle drug resistance by computational drug repositioning approach. PMID: 27626687
  34. Different from C-M-T phenotype in hereditary neuropathies caused by mutations in the HSPB1 gene. PMID: 27816334
  35. found knock down of HSPB1 further increased the proportion of apoptotic cells in hyperthermic treated melanoma cells when compared with either single agent alone, and both agents leaded to cell cycle arrest at G0/G1 or G2/M phases PMID: 27626679
  36. Data suggest that altered dimerization of HSP27 represents a good strategy for anticancer therapy in HSP27-overexpressing cancer cells. PMID: 27449291
  37. Apatorsen ( 2'-methoxyethyl-modified antisense oligonucleotide that inhibits Hsp27 expression)was tolerated at the highest dose evaluated (1000 mg). Single-agent activity was suggested by changes in tumor markers, circulating tumor cells , and stable measurable disease PMID: 27022067
  38. this results show the central role of Hsp27 in RACK1 pseudosubstrate or LPS-induced cell activation of primary leukocytes PMID: 27178349
  39. High p-Hsp27 expression is associated with cisplatin resistance in lung cancer. PMID: 26872057
  40. Low p-Hsp27 expression is associated with pancreatic cancer. PMID: 26895107
  41. The up-regulation of Hsp27 by E2 is mediated by ERalpha/Sp1. PMID: 27179757
  42. Study report a novel interaction between mutant HSPB1-P182L and the RNA binding protein PCBP1, leading to a reduction in its translational repression activity. Identifying PCBP1 mRNA targets revealed a marked prevalence for an RNA recognition motif, preferably seen in their 5' and 3'UTRs. Findings further support a role for mutant HSPB1 in neurodegenerative diseases. PMID: 28077174
  43. Hsp 70 and Hsp 27 were expressed in middle ear effusions PMID: 28964286
  44. High Hsp27 expression is associated with Thyroid Tumors. PMID: 26970173
  45. Bradykinin stimulates myofibroblast migration through protein kinase D-mediated activation of COX-2 and Hsp27. PMID: 28032559
  46. Data suggest that HSPB6 forms hetero-oligomers with HSPB1 under the following rules: (1) highly conserved motif RLFDQXFG is necessary for subunit exchange among oligomers, (2) a site about 20 residues downstream of this motif determines size of resultant hetero-oligomers, and (3) a region in the N-terminal domain that is unique to HSPB6 dictates preferential formation of heterodimers. (HSP = heat shock protein) PMID: 28487364
  47. TNF-alpha stimulates colonic myofibroblast migration through P38 MAPK-mediated activation of COX-2 and Hsp27. PMID: 27451881
  48. The potency of the sHsps to suppress aggregation of model substrates is correlated with their ability to form stable substrate complexes; especially HspB1 and HspB5, but also B3, bind tightly to a variety of proteins PMID: 27909051
  49. This work examines the molecular mechanism by which two canonical sHsps, alphaB-crystallin (alphaB-c) and Hsp27, interact with aggregation-prone alpha-syn to prevent its aggregation in vitro Both sHsps are very effective inhibitors of alpha-syn aggregation PMID: 27587396
  50. This study highlights a novel relation between serum pHSP27 and BMD in Indian women however, these findings need to be confirmed in larger studies PMID: 27241641

Show More

Hide All

Database Links

HGNC: 5246

OMIM: 602195

KEGG: hsa:3315

STRING: 9606.ENSP00000248553

UniGene: Hs.520973

Involvement In Disease
Charcot-Marie-Tooth disease 2F (CMT2F); Neuronopathy, distal hereditary motor, 2B (HMN2B)
Protein Families
Small heat shock protein (HSP20) family
Subcellular Location
Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, spindle.
Tissue Specificity
Detected in all tissues tested: skeletal muscle, heart, aorta, large intestine, small intestine, stomach, esophagus, bladder, adrenal gland, thyroid, pancreas, testis, adipose tissue, kidney, liver, spleen, cerebral cortex, blood serum and cerebrospinal f

Q&A

What are the optimal applications for Phospho-HSPB1 (Ser82) antibodies?

Phospho-HSPB1 (Ser82) antibodies are suitable for multiple applications with the following recommended dilutions:

ApplicationRecommended DilutionNotes
Western Blot1:500-1:5000Most commonly used application
Immunohistochemistry1:50-1:200Effective for tissue sections
Immunofluorescence1:50-1:200For cellular localization studies
ELISA1:5000For quantitative detection

For optimal results, each laboratory should determine specific dilutions through titration experiments. The sensitivity varies by application, with Western blotting generally offering the highest sensitivity for detecting endogenous levels of phosphorylated HSPB1 .

How can I confirm the specificity of Phospho-HSPB1 (Ser82) antibody detection?

To confirm antibody specificity:

  • Include positive controls: Use UV-stimulated HeLa cells (20 mJ/cm² ultraviolet radiation), which show increased phosphorylation at Ser82 .

  • Include negative controls: Use unstimulated cells with minimal phosphorylation .

  • Employ phosphatase treatment: Treat duplicate samples with lambda phosphatase to remove phosphate groups.

  • Use phospho-null mutants: Express S82A HSPB1 mutants that cannot be phosphorylated at this site.

  • Validate with multiple antibodies: Compare results from different clones targeting the same phosphorylation site.

The specificity of these antibodies is demonstrated by their ability to detect HSPB1 protein only when phosphorylated at Ser82 , making proper controls essential for meaningful results.

What is the expected molecular weight for phosphorylated HSPB1 in Western blot applications?

  • Post-translational modifications: Additional phosphorylation sites (Ser15, Ser78) may cause mobility shifts.

  • Oligomerization states: HSPB1 forms various oligomeric structures.

  • Proteolytic fragments: Sample preparation may generate cleavage products.

When running SDS-PAGE for Phospho-HSPB1 detection, use 12-15% gels for optimal resolution in this molecular weight range. The presence of phosphorylation may cause slight mobility shifts compared to unphosphorylated HSPB1 .

How should I design experiments to study stress-induced HSPB1 phosphorylation?

Design experiments to study stress-induced HSPB1 phosphorylation with these methodological considerations:

  • Time-course analysis: Monitor phosphorylation at multiple time points (5, 15, 30, 60 minutes, and 2, 4, 8 hours) after stress induction.

  • Stress stimuli options:

    • Heat shock (42-45°C)

    • Oxidative stress (H₂O₂ treatment)

    • UV radiation (20 mJ/cm²)

    • Mechanical stress (for muscle or endothelial cells)

    • Inflammatory cytokines

  • Pathway inhibitors: Include MAPKAPK2/3 inhibitors to confirm the kinase pathway involved.

  • Multiple phosphorylation sites: Monitor Ser15, Ser78, and Ser82 simultaneously to understand the phosphorylation pattern.

  • Subcellular localization: Combine with fractionation or immunofluorescence to track phospho-HSPB1 translocation to Z-discs and areas of traction force .

This comprehensive approach allows for mechanistic understanding of the temporal and spatial aspects of HSPB1 phosphorylation under various stress conditions.

How can I distinguish between the effects of different HSPB1 phosphorylation sites in my research?

To differentiate the specific roles of individual phosphorylation sites:

  • Use site-specific phospho-antibodies: Apply antibodies targeting single phosphorylation sites (S15, S78, S82) in parallel experiments .

  • Employ phosphomimetic mutants: Generate S15D, S78D, and S82D mutants (D = aspartic acid) to mimic constitutive phosphorylation.

  • Create phospho-null mutants: Use S15A, S78A, and S82A mutants (A = alanine) to prevent phosphorylation.

  • Analyze combinatorial mutations: Study double mutants to understand synergistic effects of multiple sites.

  • Utilize kinase-specific inhibitors: Apply inhibitors of MAPKAPK2/3 (which phosphorylates all three sites) versus MAPKAPK5 (which has different site preferences) .

This approach enables detailed mapping of site-specific functions, as phosphorylation at Ser82 specifically affects HSPB1 oligomerization and chaperone activity, while other sites may influence different functions like F-actin rearrangement .

What methodological approaches can detect changes in HSPB1 oligomerization after Ser82 phosphorylation?

Phosphorylation at Ser82 significantly affects HSPB1 oligomerization. To study these changes:

  • Non-denaturing gel electrophoresis: Run native PAGE to preserve protein complexes.

  • Size-exclusion chromatography: Separate oligomers by size to quantify shifts in oligomeric distribution.

  • Chemical crosslinking: Use crosslinkers followed by SDS-PAGE to capture transient oligomeric states.

  • Dynamic light scattering: Measure the hydrodynamic radius of HSPB1 complexes.

  • Immunofluorescence co-localization: Visualize spatial reorganization of HSPB1 after phosphorylation.

  • Proximity ligation assays: Detect protein-protein interactions within oligomers.

This multi-method approach reveals how phosphorylation by MAPKAPK2 and MAPKAPK3 at Ser82 dissociates HSPB1 from large small heat-shock protein (sHsps) oligomers, which directly impacts its chaperone activity and ability to protect against oxidative stress .

How can I optimize signal detection for low abundance Phospho-HSPB1 (Ser82)?

For detecting low levels of phosphorylated HSPB1:

  • Enrichment strategies:

    • Immunoprecipitate total HSPB1 first, then probe with phospho-specific antibody

    • Use phosphoprotein enrichment kits before Western blotting

    • Apply phosphatase inhibitors (10 mM sodium fluoride, 1 mM sodium orthovanadate) during sample preparation

  • Signal enhancement:

    • Use highly sensitive ECL substrates for Western blotting

    • Employ biotin-streptavidin amplification systems

    • Utilize secondary antibodies with higher HRP ratios

  • Background reduction:

    • Increase blocking time and concentration (5% BSA recommended)

    • Add 0.1% Tween-20 to antibody dilutions

    • Optimize antibody concentrations through titration

  • Exposure optimization:

    • Use multiple exposure times

    • Consider digital imaging systems with adjustable sensitivity

These approaches can significantly improve detection of phosphorylated HSPB1 in samples with low basal phosphorylation levels .

What are the critical variables affecting reproducibility in Phospho-HSPB1 (Ser82) detection?

Key factors influencing experimental reproducibility include:

VariableCritical ConsiderationsRecommendation
Sample preparationRapid phosphatase activationProcess samples immediately on ice with phosphatase inhibitors
Cell densityAffects stress responseStandardize at 70-80% confluence for adherent cells
Antibody selectionClone-specific performanceCompare antibody performance across applications
Blocking solutionCan affect phospho-epitope detectionUse 5% BSA rather than milk for phospho-specific antibodies
Stimulation protocolVariable induction of phosphorylationStandardize stress intensity and duration (e.g., 20 mJ/cm² UV)
Detection methodSensitivity variationsMatch method sensitivity to expected phosphorylation levels

Consistent control of these variables significantly improves experiment-to-experiment reproducibility. Document detailed protocols including lot numbers of antibodies and exact treatment conditions for maximum reproducibility .

How should I validate Phospho-HSPB1 (Ser82) antibody performance across different cell types?

To validate antibody performance across different cell types:

  • Perform initial testing in well-characterized models:

    • HeLa cells show robust phosphorylation response to UV radiation

    • Consider positive control lysates from vendors if available

  • Cross-species validation protocol:

    • Test antibody reactivity in human, mouse, and rat samples in parallel

    • Note that many phospho-HSPB1 antibodies react with human and rat, but validation for mouse may be required

  • Cell type-specific considerations:

    • Muscle cells: Higher basal HSPB1 expression

    • Neuronal cells: Different subcellular distribution

    • Cancer cell lines: May have altered signaling pathways

  • Validation experiment design:

    • Apply known stimulus (heat shock, oxidative stress)

    • Compare response magnitude across cell types

    • Confirm phosphorylation with secondary approaches (mass spectrometry)

  • Document cell-specific optimal conditions:

    • Antibody dilution may need adjustment by cell type

    • Exposure to detection reagents may require optimization

    • Blocking conditions might need modification

This systematic approach ensures reliable results when transferring methods between different experimental systems .

How does phosphorylation at Ser82 specifically affect HSPB1 function compared to other phosphorylation sites?

Phosphorylation at Ser82 has distinct functional consequences:

  • Structural changes:

    • Ser82 phosphorylation primarily affects the oligomerization state, reducing large oligomers to smaller units

    • Unlike Ser15, Ser82 phosphorylation more directly impacts the alpha-crystallin domain interactions

  • Cellular localization:

    • Phosphorylation at Ser82 triggers translocation to Z-discs and areas of mechanical stress

    • This differs from other phosphorylation sites that may preferentially direct HSPB1 to different subcellular compartments

  • Chaperone activity:

    • Ser82 phosphorylation specifically impairs chaperone activity against certain protein substrates

    • This impairment affects protection against oxidative stress differently than other phosphorylation sites

  • Cytoskeletal interactions:

    • While MAPKAPK5-mediated phosphorylation affects F-actin rearrangement, Ser82 phosphorylation by MAPKAPK2/3 has distinct effects on interactions with mechanosensitive clients like FLNC

  • Pathway specificity:

    • Ser82 phosphorylation is particularly relevant in cellular stress response pathways including mechanical stress and UV radiation response

These distinct functions highlight why site-specific phospho-antibodies are crucial for understanding the nuanced roles of HSPB1 in various cellular contexts .

How can Phospho-HSPB1 (Ser82) serve as a biomarker in disease studies?

Phosphorylated HSPB1 at Ser82 has emerging value as a disease biomarker:

  • Cancer applications:

    • Serves as a potential biomarker to predict chemotherapy-induced autophagy in osteosarcoma response

    • Can indicate activation of stress response pathways in carcinoma cells

  • Methodological approaches for biomarker studies:

    • Tissue microarray analysis with phospho-specific antibodies

    • Quantitative Western blotting with reference standards

    • Development of phospho-HSPB1 ELISA assays for patient samples

    • Correlation with treatment outcomes and survival data

  • Neurological disorders:

    • Monitoring axonal transport dysfunction through phospho-HSPB1 levels

    • Potential indicator of stress response in neurodegenerative conditions

  • Cardiovascular applications:

    • Marker for cellular stress in cardiomyocytes during ischemia-reperfusion

    • Potential indicator of mechanical stress in vascular disorders

  • Methodological considerations:

    • Standardization of sample collection protocols is critical

    • Normalization to total HSPB1 levels improves biomarker reliability

    • Multiple phosphorylation sites should be analyzed in parallel

These applications highlight the translational relevance of phospho-HSPB1 research beyond basic science contexts .

What are the emerging techniques for studying the temporal dynamics of HSPB1 Ser82 phosphorylation?

Advanced methodologies for temporal analysis include:

  • Live-cell imaging approaches:

    • Phospho-specific FRET biosensors for real-time monitoring

    • Split luciferase complementation assays for phosphorylation-dependent interactions

    • Optogenetic tools to trigger localized HSPB1 phosphorylation

  • Mass spectrometry strategies:

    • Parallel reaction monitoring (PRM) for quantitative analysis of multiple phosphorylation sites

    • SILAC labeling for temporal profiling of phosphorylation dynamics

    • Phosphoproteomics with enrichment for low abundance phosphopeptides

  • Single-cell analysis methods:

    • Imaging mass cytometry with phospho-specific antibodies

    • Single-cell Western blotting for heterogeneity assessment

    • Flow cytometry with phospho-specific antibodies for high-throughput analysis

  • Computational approaches:

    • Mathematical modeling of phosphorylation/dephosphorylation kinetics

    • Machine learning for pattern recognition in phosphorylation dynamics

    • Systems biology integration of phosphorylation with downstream effects

These emerging techniques allow researchers to move beyond static measurements to understand the dynamic regulation of HSPB1 phosphorylation in response to various cellular stresses and signaling events .

How should researchers approach studying the interplay between different HSPB1 phosphorylation sites?

A comprehensive experimental strategy includes:

  • Multiplex detection approaches:

    • Multiplex Western blotting with differently labeled antibodies against each phosphorylation site

    • Sequential reprobing of membranes with different phospho-specific antibodies

    • Mass spectrometry for simultaneous quantification of all phosphorylation sites

  • Kinase manipulation strategies:

    • Selective inhibition of MAPKAPK2/3 (affects Ser15, Ser78, Ser82) versus MAPKAPK5 (different site preference)

    • Knockdown/knockout of specific kinases

    • Expression of constitutively active kinase mutants

  • Combinatorial mutation analysis:

    • Single site phospho-null mutants (S15A, S78A, S82A)

    • Double mutants to assess site interdependence

    • Triple mutants compared to wild-type HSPB1

  • Temporal resolution experiments:

    • High-resolution time course analysis after stimulus

    • Pulse-chase labeling to track phosphorylation/dephosphorylation kinetics

    • Single-cell analysis to detect population heterogeneity

This integrated approach reveals how multiple phosphorylation events coordinate to regulate HSPB1 function in response to diverse cellular stresses .

What analytical methods best distinguish between singly and multiply phosphorylated forms of HSPB1?

To differentiate between phosphorylation states:

  • Electrophoretic techniques:

    • Phos-tag SDS-PAGE to separate proteins based on phosphorylation state

    • 2D gel electrophoresis (isoelectric focusing followed by SDS-PAGE)

    • Capillary electrophoresis for high-resolution separation

  • Mass spectrometry approaches:

    • Selected/multiple reaction monitoring (SRM/MRM) for targeted quantification

    • Electron transfer dissociation (ETD) for intact phosphopeptide analysis

    • Top-down proteomics for intact protein analysis with phosphorylation state information

  • Chromatographic methods:

    • Immobilized metal affinity chromatography (IMAC) with stepwise elution

    • Ion exchange chromatography to separate by charge differences

    • Hydrophilic interaction liquid chromatography (HILIC) for phosphopeptide enrichment

  • Antibody-based approaches:

    • Sequential immunoprecipitation with different phospho-specific antibodies

    • Multiplexed ELISA systems with site-specific detection

These methods allow researchers to determine not only the presence of phosphorylation but also to quantify the relative abundance of different phosphorylated species, providing insights into the dynamics of HSPB1 regulation .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.